登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patients
ClinicalTrials.gov 上登记的一项乳腺癌开放试验。牵头方不是本站收录的医院;本站收录的 1 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07235176,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Local recurrent or metastatic advanced ER+/HER2- breast cancer confirmed by histopathology or cytopathology;
入选标准第 5 条
Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1.
排除标准第 4 条
ECOG score: 0-1
入选标准第 3 条
Baseline presence of at least one measurable lesion according to the RECIST v1.1;
入选标准第 7 条
Subjects have other active malignant tumors within 3 years before the first use of the investigational drug.
排除标准第 6 条
Female subjects with fertility and male subjects must agree to use highly effective contraception during the study treatment period and within 180 days after the last medication;
入选标准第 9 条
Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation.
入选标准第 10 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07235176,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Volunteer to participate in this study, sign an informed consent form and have good compliance; Age ≥ 18 years old, Male or female ECOG score: 0-1 Expected survival ≥ 12 weeks Local recurrent or metastatic advanced ER+/HER2- breast cancer confirmed by histopathology or cytopathology; Failed to at least one therapy line of endocrine therapy ; Baseline presence of at least one measurable lesion according to the RECIST v1.1; The functional level of important organs is basically normal, meeting the requirements of the scheme; Female subjects with fertility and male subjects must agree to use highly effective contraception during the study treatment period and within 180 days after the last medication; Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation. Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent.排除标准:Exclusion Criteria:
Subjects have received live or attenuated live vaccines within 4 weeks before the first use of the investigational drug. Subjects have undergone major organ surgery within 4 weeks before the first use of the investigational drug. Subjects require long-term or high-dose use of non-steroidal drugs. Subjects have not recovered from adverse events (AEs) caused by previous anti-tumor treatment to ≤ grade 1. Subjects have a known or suspected severe allergy to the investigational drug or any of its components. Subjects have other active malignant tumors within 3 years before the first use of the investigational drug. Subjects have brain metastases and/or carcinomatous meningitis or leptomeningeal disease. Subjects have active tuberculosis, radiation pneumonitis, drug-induced pneumonitis, pulmonary fibrosis, or other diseases, symptoms, or signs of severe lung function impairment. Subjects are unable to swallow tablets or had gastrointestinal abnormalities that the investigator assessed as potentially affecting drug absorption. Subjects have a history of severe cardiovascular or cerebrovascular disease within 6 months before the first use of the investigational drug. Subjects have a hypertension medial history that blood is not well controlled despite treatment with multiple antihypertension drugs.
引自 ClinicalTrials.gov, NCT07235176, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07235176,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。